gemfibrozil has been researched along with Hyperlipoproteinemia Type II in 46 studies
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial combined hyperlipidemia." | 5.06 | Combination drug therapy for familial combined hyperlipidemia. ( Bilheimer, DW; East, C; Grundy, SM, 1988) |
| "In the control group (n=18), a hypolipidemiant diet alone was indicated." | 2.71 | Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. ( Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R, 2003) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| "Gemfibrozil (G) is a widely used and highly effective fibric acid derivative." | 2.67 | Activity profile of gemfibrozil on the major plasma lipoprotein parameters. ( Bertoli, M; Calabresi, L; Chiesa, G; Franceschini, G; Gianfranceschi, G; Maderna, P; Sirtori, CR; Vaccarino, V, 1992) |
| " Group 1 received the standard gemfibrozil dosage of two 300-mg capsules 2 times a day, for a total daily dosage equal to 1,200 mg." | 2.66 | A comparison of different formulations and dosage administrations of gemfibrozil. ( Koskinen, P; Kovanen, PT; Manninen, V, 1986) |
| "At baseline the patients with familial hypercholesterolemia had a markedly reduced or missing HDL2 subfraction and their HDL3 was more dense with reduced content of cholesteryl ester and increased content of triglyceride compared with HDL of control subjects with normal lipid values." | 1.28 | Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia. ( Tikkanen, MJ; Tilly-Kiesi, M, 1992) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (47.83) | 18.7374 |
| 1990's | 23 (50.00) | 18.2507 |
| 2000's | 1 (2.17) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández, C | 1 |
| Lecube, A | 1 |
| Barberá, G | 1 |
| Chacón, P | 1 |
| Lima, J | 1 |
| Simó, R | 1 |
| Torstila, I | 1 |
| Kaukola, S | 1 |
| Manninen, V | 4 |
| Virtamo, J | 1 |
| Mälkönen, M | 1 |
| Nash, DT | 1 |
| Dahlén, G | 1 |
| Gillnäs, T | 1 |
| Børresen, AL | 1 |
| Berg, K | 1 |
| Ericson, C | 1 |
| Franceschini, G | 3 |
| Lovati, MR | 1 |
| Manzoni, C | 1 |
| Michelagnoli, S | 1 |
| Pazzucconi, F | 1 |
| Gianfranceschi, G | 3 |
| Vecchio, G | 1 |
| Sirtori, CR | 3 |
| Bertolotti, M | 1 |
| Concari, M | 1 |
| Loria, P | 1 |
| Abate, N | 1 |
| Pinetti, A | 1 |
| Guicciardi, ME | 1 |
| Carulli, N | 1 |
| Tallis, GA | 1 |
| Shephard, MD | 1 |
| Whiting, MJ | 1 |
| Polakowska, M | 1 |
| Broda, G | 1 |
| Rywik, S | 1 |
| Piotrowski, W | 1 |
| Bednarska, M | 1 |
| Kuźmińska, A | 1 |
| Pytlak, A | 1 |
| Chotkowska, E | 1 |
| Branchi, A | 1 |
| Rovellini, A | 1 |
| Sommariva, D | 1 |
| Gugliandolo, AG | 1 |
| Fasoli, A | 1 |
| Smith, GW | 1 |
| Hurst, NP | 1 |
| Bruckert, E | 1 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Jones, PH | 2 |
| Pownall, HJ | 1 |
| Patsch, W | 1 |
| Herd, JA | 1 |
| Farmer, JA | 2 |
| Payton-Ross, C | 1 |
| Kimball, KT | 1 |
| Gotto, AM | 3 |
| Morrisett, JD | 1 |
| Brosche, T | 1 |
| Kipfmüller, G | 1 |
| Kockx, M | 1 |
| de Maat, MP | 1 |
| Knipscheer, HC | 1 |
| Kastelein, JJ | 1 |
| Kluft, C | 1 |
| Princen, HM | 1 |
| Kooistra, T | 1 |
| Durrington, PN | 1 |
| Mackness, MI | 1 |
| Bhatnagar, D | 1 |
| Julier, K | 1 |
| Prais, H | 1 |
| Arrol, S | 1 |
| Morgan, J | 1 |
| Wood, GN | 1 |
| Bergemann, R | 1 |
| Brandt, A | 1 |
| Siegrist, W | 1 |
| Vaccarino, V | 2 |
| Chiesa, G | 2 |
| Maderna, P | 1 |
| Bertoli, M | 1 |
| Calabresi, L | 1 |
| Ceska, R | 1 |
| Sobra, J | 1 |
| Toschnerová, H | 1 |
| Traurig, J | 1 |
| Tilly-Kiesi, M | 2 |
| Tikkanen, MJ | 4 |
| Bell, DS | 1 |
| Wagenknecht, LE | 1 |
| Stange, EF | 1 |
| Osenbrügge, M | 1 |
| Rustan, M | 1 |
| Reimann, F | 1 |
| Schneider, A | 1 |
| Ditschuneit, HH | 1 |
| Ditschuneit, H | 1 |
| Monova, D | 1 |
| Petrova, V | 1 |
| Belovezhdov, N | 1 |
| Ojala, JP | 1 |
| Helve, E | 1 |
| Carlson, LA | 1 |
| Koskinen, P | 2 |
| Manttari, M | 1 |
| Huttunen, JK | 1 |
| Canter, D | 1 |
| Frick, HM | 1 |
| Sirtori, M | 1 |
| Corder, CN | 1 |
| Kloer, HU | 1 |
| Price, MD | 1 |
| Illingworth, DR | 1 |
| Bacon, S | 1 |
| Kremer, P | 1 |
| Marowski, C | 1 |
| Jones, C | 1 |
| Acacia, E | 1 |
| Nightingale, SL | 1 |
| Jones, AF | 1 |
| Hughes, EA | 1 |
| Cramb, R | 1 |
| Houlston, R | 1 |
| Quiney, J | 1 |
| Watts, GF | 1 |
| Lewis, B | 1 |
| East, C | 1 |
| Bilheimer, DW | 1 |
| Grundy, SM | 1 |
| Hunninghake, DB | 1 |
| Peters, JR | 1 |
| Sznajd, J | 2 |
| Malczewska-Malec, M | 2 |
| Idzior-Waluś, B | 2 |
| Jamska, B | 1 |
| Nowacki, G | 2 |
| Iwanejko, J | 1 |
| Kovanen, PT | 1 |
| Davignon, J | 1 |
| Weintraub, MS | 1 |
| Eisenberg, S | 1 |
| Breslow, JL | 1 |
| Nikkilä, EA | 1 |
| Kane, JP | 1 |
| Havel, RJ | 1 |
| Scott, LW | 1 |
| Schaefer, EJ | 1 |
| Levy, RI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gemfibrozil and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfib | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
17 trials available for gemfibrozil and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hy | 2003 |
Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
Topics: Adult; Aprotinin; Body Weight; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Female; Gemf | 1982 |
Clinical results with gemfibrozil and background to the Helsinki Heart Study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studi | 1983 |
Effect of gemfibrozil on serum lipid levels.
Topics: Cholesterol; Clinical Trials as Topic; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1980 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fasting; Gemfibrozil; Humans; Hyperlipoprote | 1996 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gem | 1997 |
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Prote | 1998 |
Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Ge | 1992 |
Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Topics: Apolipoproteins; Cholesterol; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-Co | 1989 |
CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
Topics: Apolipoproteins; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; Hyperli | 1989 |
Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Fema | 1989 |
Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.
Topics: Adult; Aged; Argentina; Arteriosclerosis; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; | 1989 |
Combination drug therapy for familial combined hyperlipidemia.
Topics: Adult; Cholelithiasis; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipi | 1988 |
[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Gemfibrozil; Humans | 1987 |
[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Topics: Apolipoproteins; Cholesterol; Clinical Trials as Topic; Gemfibrozil; Humans; Hyperlipoproteinemia Ty | 1987 |
A comparison of different formulations and dosage administrations of gemfibrozil.
Topics: Administration, Oral; Adult; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Administratio | 1986 |
24 other studies available for gemfibrozil and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Gemfibrozil--a new lipid lowering agent.
Topics: Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; | 1980 |
Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction.
Topics: Adult; Aged; Analysis of Variance; Apolipoproteins; Carrier Proteins; Cholesterol; Cholesterol Ester | 1995 |
Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans.
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Gemfibrozil; Humans; Hyper | 1995 |
Lipoprotein profiling by high performance gel chromatography.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chroma | 1994 |
[Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
Topics: Adolescent; Adult; Aged; Cholesterol; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hyperlipoprote | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibr | 1993 |
Vasculitis, Raynaud's phenomenon and polyarthritis associated with gemfibrozil therapy.
Topics: Adult; Arthritis; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Male; Raynaud Disease; Vasculit | 1993 |
[Gemfibrozil in the elderly. Effects on lipid metabolism].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Fatty Acids, Nonesterified; Female; Ge | 1996 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperl | 1993 |
[Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia].
Topics: Adult; Aged; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Heterozygote; Humans; Hyper | 1992 |
Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Centrifugation, Density Gradient; Chemical Fractiona | 1992 |
Effect of gemfibrozil on intermediate-density lipoproteins in NIDDM patients. A retrospective study.
Topics: Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoprot | 1992 |
Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Cells, Cultured; Cholesterol; Cholesterol, HDL; C | 1991 |
[Gemfibrozil in the treatment of hyperlipoproteinemias].
Topics: Adult; Aged; Cholesterol; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hy | 1991 |
Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia.
Topics: Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin | 1991 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic A | 1990 |
Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipoprotein | 1990 |
From the Food and Drug Administration.
Topics: Adult; Azides; Drug Labeling; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Male; Middl | 1989 |
Gemfibrozil plus cholestyramine in familial hypercholesterolaemia.
Topics: Adult; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Gemfib | 1988 |
Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Topics: Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Topics: Cholestyramine Resin; Chylomicrons; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia | 1987 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |